Credo Life Science
Posted on 27th January 2022
Dexlansoprazole Manufacturer: Dual Delayed-Release Technology and Supplier Considerations
Dexlansoprazole is a proton pump inhibitor known for its dual delayed-release design, which was developed to provide acid suppression over a longer period of time than conventional single-release products. For pharmaceutical companies exploring dexlansoprazole, whether as an active ingredient or as delayed-release granules, the technical demands are considerable. This guide explains the drug, the technology behind its formulation and what to check in a manufacturer.
What Is Dexlansoprazole?
Dexlansoprazole is the R-enantiomer of lansoprazole. Like other proton pump inhibitors, it reduces gastric acid production by blocking the proton pump in the stomach lining. It is used in the management of conditions such as erosive oesophagitis and gastro-oesophageal reflux disease, under medical supervision.
The Challenge: Acid Sensitivity - Proton pump inhibitors are unstable in acidic conditions and degrade quickly when exposed to stomach acid. Their formulations must therefore protect the drug during passage through the stomach and release it in the intestine, where it is absorbed. This makes enteric coating and careful stabilisation essential.
Dual Delayed-Release Technology
The Concept and Technical Demands
The reference dosage form is a capsule containing two types of enteric-coated granules, each designed to release the drug at a different pH. One type releases in the proximal small intestine and the other further along the intestine. The result is two release phases that extend the period of drug exposure.
Why It Is Technically Demanding: Making two populations of pellets with different dissolution thresholds, and combining them in a defined ratio, requires accurate polymer selection, coating control and blending. Each population must be consistent, as must the final capsule fill.
Components of Dexlansoprazole Granules
Core ingredients and structural layers:
- Inert starter cores such as sugar spheres
- A drug layer containing dexlansoprazole with suitable alkaline stabilisers and binders
- A protective sub-coat that separates the drug from acidic polymers
- Enteric coatings of different polymers or compositions to release at different pH values
- Processing aids such as plasticisers and anti-tacking agents
Manufacturing Considerations
Stabilisation, Coating Control & Blending
Stabilisation of the Drug: Because dexlansoprazole is sensitive to moisture, acid and heat, processing conditions are optimised to limit degradation, and the use of alkaline stabilisers and low-moisture processing is common.
Coating Control: Coating levels, spray parameters and curing conditions directly affect dissolution. Slight variations can shift the release pH and alter performance, so tight in-process controls are vital.
Blending and Filling: Different pellet populations must be blended homogeneously and filled accurately so that each capsule has the intended ratio.
Quality Attributes to Check
Critical quality parameters include:
- Assay, related substances and enantiomeric purity
- Acid-resistance and buffer-stage dissolution at the relevant pH steps
- Particle size, density and sphericity
- Moisture content and residual solvents
- Content uniformity of the final blend
- Stability under accelerated and long-term conditions
- Polymorphic form of the active ingredient, if applicable
Choosing a Dexlansoprazole Manufacturer
Technical Expertise, Compliance and IP
Look for experience with acid-labile drugs, enteric coating and multi-population systems. Check the quality management system, GMP compliance and the documentation provided, including specifications, analytical methods and stability data.
Buyers should seek legal advice on freedom to operate in their intended markets, and check supply assurance including lead times and raw material sourcing.
Stability and Storage: Dexlansoprazole granules are generally stored in tightly closed, moisture-protective packaging at the temperature specified, away from light and heat.
Documents and Support Buyers Commonly Request
Essential technical documentation packages:
- Product specification and certificate of analysis
- Process flow chart and release criteria
- Stability summaries
- Information on residual solvents and excipients
- Support for technical queries during development
Why Choose Credo Life Sciences?
Credo Life Sciences focuses on pharmaceutical pellets and granules for formulation companies that need consistent quality, dependable supply and clear technical communication. We understand that a multiparticulate ingredient is only as good as its reproducibility from batch to batch, so our approach centres on controlled processes, thorough documentation and responsive support for your development and commercial needs. We work as a long-term partner to our customers, not just a vendor.
Dexlansoprazole is a sophisticated product in which formulation science plays a central role. Success depends on controlling stability, coating and blending with precision. If you are evaluating a dexlansoprazole manufacturer, discuss your requirements with our team.
Partner with Credo Life Sciences for your pellet and granule requirements. Contact our team to discuss specifications and quotations.
Frequently Asked Questions
What does dual delayed release mean?
It means that the dosage form contains two sets of granules that release the drug at different points in the intestine, extending the period of drug exposure.
Can the granules be combined in one capsule?
Yes. The reference approach fills two granule types in a defined ratio into one capsule.
Why is moisture control so important?
Moisture can degrade the drug and affect the performance of the coating.